---
document_datetime: 2026-01-07 17:20:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord.html
document_name: cabazitaxel-accord.html
version: success
processing_time: 0.1649088
conversion_datetime: 2026-01-10 11:11:02.835993
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cabazitaxel Accord

[RSS](/en/individual-human-medicine.xml/67303)

##### Authorised

This medicine is authorised for use in the European Union

cabazitaxel Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cabazitaxel Accord](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76298)
- [More information on Cabazitaxel Accord](#more-information-on-cabazitaxel-accord-1591)
- [More information on Cabazitaxel Accord](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Cabazitaxel Accord is a cancer medicine used to treat men with metastatic castration-resistant prostate cancer. This is a cancer that affects the prostate gland that produces the liquid in semen (prostate fluid). Cabazitaxel Accord is used when the cancer has spread to other parts of the body (metastatic) despite treatments to prevent the production of testosterone or after surgical removal of the testes (castration). Cabazitaxel Accord is used in combination with prednisone or prednisolone (anti-inflammatory medicines) in patients who have previously been treated with docetaxel (another cancer medicine).

Cabazitaxel Accord contains the active substance cabazitaxel and is a 'hybrid' and a 'generic' medicine. This means that it is similar to a reference medicine containing the same active substance, but comes in a different concentration and is prepared (diluted) differently. The reference medicine for Cabazitaxel Accord is Jevtana.

Expand section

Collapse section

## How is Cabazitaxel Accord used?

Cabazitaxel Accord can only be obtained with a prescription and should only be used in units specialising in chemotherapy (medicines to treat cancer) under the supervision of a doctor experienced in the use of chemotherapy.

Cabazitaxel Accord is available as a concentrate to be made up into a solution for infusion (drip) into a vein. It is given once every three weeks as an infusion lasting one hour, at a dose based on the patient's weight and height. It is given in combination with prednisone or prednisolone, taken daily throughout treatment.

The doctor may have to reduce the dose of Cabazitaxel Accord or stop treatment if the patient has certain side effects. The dose should also be reduced in patients with mildly reduced liver function.  Cabazitaxel Accord must not be given to patients with moderately or severely reduced liver function.

Before receiving Cabazitaxel Accord infusion, patients should first be given medicines to prevent allergic reactions and medicines to prevent vomiting.

For more information about using Cabazitaxel Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Cabazitaxel Accord work?

The active substance in Cabazitaxel Accord, cabazitaxel, belongs to the group of cancer medicines known as 'taxanes'. Cabazitaxel works by blocking the ability of cancer cells to break down their internal 'skeleton', which allows them to divide and multiply. With their skeleton still in place, the cells cannot divide and eventually die. Cabazitaxel Accord also affects non-cancer cells, such as blood and nerve cells, which can cause side effects.

## How has Cabazitaxel Accord been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Jevtana, and do not need to be repeated for Cabazitaxel Accord.

As for every medicine, the company provided studies on the quality of Cabazitaxel Accord. There was no need for bioequivalence studies to investigate whether Cabazitaxel Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Cabazitaxel Accord is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Cabazitaxel Accord?

Because Cabazitaxel Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Cabazitaxel Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Cabazitaxel Accord has been shown to have comparable quality and to be bioequivalent to Jevtana. Therefore, the Agency's view was that, as for Jevtana, the benefits of Cabazitaxel Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Cabazitaxel Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cabazitaxel Accord have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Cabazitaxel Accord are continuously monitored. Side effects reported with Cabazitaxel Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Cabazitaxel Accord

Cabazitaxel Accord received a marketing authorisation valid throughout the EU on 28 August 2020.

Cabazitaxel Accord : EPAR - Medicine overview

Reference Number: EMA/242602/2020

English (EN) (130.51 KB - PDF)

**First published:** 28/10/2020

[View](/en/documents/overview/cabazitaxel-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-664)

български (BG) (168.71 KB - PDF)

**First published:**

28/10/2020

[View](/bg/documents/overview/cabazitaxel-accord-epar-medicine-overview_bg.pdf)

español (ES) (144.87 KB - PDF)

**First published:**

28/10/2020

[View](/es/documents/overview/cabazitaxel-accord-epar-medicine-overview_es.pdf)

čeština (CS) (166.46 KB - PDF)

**First published:**

28/10/2020

[View](/cs/documents/overview/cabazitaxel-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (144.93 KB - PDF)

**First published:**

28/10/2020

[View](/da/documents/overview/cabazitaxel-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (150.26 KB - PDF)

**First published:**

28/10/2020

[View](/de/documents/overview/cabazitaxel-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.26 KB - PDF)

**First published:**

28/10/2020

[View](/et/documents/overview/cabazitaxel-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (169.1 KB - PDF)

**First published:**

28/10/2020

[View](/el/documents/overview/cabazitaxel-accord-epar-medicine-overview_el.pdf)

français (FR) (147.18 KB - PDF)

**First published:**

28/10/2020

[View](/fr/documents/overview/cabazitaxel-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (165.39 KB - PDF)

**First published:**

28/10/2020

[View](/hr/documents/overview/cabazitaxel-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (143.94 KB - PDF)

**First published:**

28/10/2020

[View](/it/documents/overview/cabazitaxel-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (174.93 KB - PDF)

**First published:**

28/10/2020

[View](/lv/documents/overview/cabazitaxel-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.13 KB - PDF)

**First published:**

28/10/2020

[View](/lt/documents/overview/cabazitaxel-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (164.45 KB - PDF)

**First published:**

28/10/2020

[View](/hu/documents/overview/cabazitaxel-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (167.73 KB - PDF)

**First published:**

28/10/2020

[View](/mt/documents/overview/cabazitaxel-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (146.08 KB - PDF)

**First published:**

28/10/2020

[View](/nl/documents/overview/cabazitaxel-accord-epar-medicine-overview_nl.pdf)

polski (PL) (169.93 KB - PDF)

**First published:**

28/10/2020

[View](/pl/documents/overview/cabazitaxel-accord-epar-medicine-overview_pl.pdf)

português (PT) (145.69 KB - PDF)

**First published:**

28/10/2020

[View](/pt/documents/overview/cabazitaxel-accord-epar-medicine-overview_pt.pdf)

română (RO) (163.42 KB - PDF)

**First published:**

28/10/2020

[View](/ro/documents/overview/cabazitaxel-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (166.21 KB - PDF)

**First published:**

28/10/2020

[View](/sk/documents/overview/cabazitaxel-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (163.85 KB - PDF)

**First published:**

28/10/2020

[View](/sl/documents/overview/cabazitaxel-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (143.56 KB - PDF)

**First published:**

28/10/2020

[View](/fi/documents/overview/cabazitaxel-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (144.73 KB - PDF)

**First published:**

28/10/2020

[View](/sv/documents/overview/cabazitaxel-accord-epar-medicine-overview_sv.pdf)

Cabazitaxel Accord : EPAR - Risk-management-plan summary

English (EN) (116.73 KB - PDF)

**First published:** 28/10/2020

**Last updated:** 16/01/2023

[View](/en/documents/rmp-summary/cabazitaxel-accord-epar-risk-management-plan-summary_en.pdf)

## Product information

Cabazitaxel Accord : EPAR - Product information

English (EN) (610.23 KB - PDF)

**First published:** 17/12/2020

**Last updated:** 07/01/2026

[View](/en/documents/product-information/cabazitaxel-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-365)

български (BG) (903.86 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/bg/documents/product-information/cabazitaxel-accord-epar-product-information_bg.pdf)

español (ES) (976.9 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/es/documents/product-information/cabazitaxel-accord-epar-product-information_es.pdf)

čeština (CS) (1.01 MB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/cs/documents/product-information/cabazitaxel-accord-epar-product-information_cs.pdf)

dansk (DA) (758.89 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/da/documents/product-information/cabazitaxel-accord-epar-product-information_da.pdf)

Deutsch (DE) (793.97 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/de/documents/product-information/cabazitaxel-accord-epar-product-information_de.pdf)

eesti keel (ET) (676.34 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/et/documents/product-information/cabazitaxel-accord-epar-product-information_et.pdf)

ελληνικά (EL) (1.01 MB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/el/documents/product-information/cabazitaxel-accord-epar-product-information_el.pdf)

français (FR) (814.14 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/fr/documents/product-information/cabazitaxel-accord-epar-product-information_fr.pdf)

hrvatski (HR) (650.03 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/hr/documents/product-information/cabazitaxel-accord-epar-product-information_hr.pdf)

íslenska (IS) (657.35 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/is/documents/product-information/cabazitaxel-accord-epar-product-information_is.pdf)

italiano (IT) (751.02 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/it/documents/product-information/cabazitaxel-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (834.11 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/lv/documents/product-information/cabazitaxel-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (855.96 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/lt/documents/product-information/cabazitaxel-accord-epar-product-information_lt.pdf)

magyar (HU) (876.56 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/hu/documents/product-information/cabazitaxel-accord-epar-product-information_hu.pdf)

Malti (MT) (829.88 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/mt/documents/product-information/cabazitaxel-accord-epar-product-information_mt.pdf)

Nederlands (NL) (744.01 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/nl/documents/product-information/cabazitaxel-accord-epar-product-information_nl.pdf)

norsk (NO) (789.63 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/no/documents/product-information/cabazitaxel-accord-epar-product-information_no.pdf)

polski (PL) (706.88 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/pl/documents/product-information/cabazitaxel-accord-epar-product-information_pl.pdf)

português (PT) (747.37 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/pt/documents/product-information/cabazitaxel-accord-epar-product-information_pt.pdf)

română (RO) (758.61 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/ro/documents/product-information/cabazitaxel-accord-epar-product-information_ro.pdf)

slovenčina (SK) (821.07 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/sk/documents/product-information/cabazitaxel-accord-epar-product-information_sk.pdf)

slovenščina (SL) (732.05 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/sl/documents/product-information/cabazitaxel-accord-epar-product-information_sl.pdf)

Suomi (FI) (842.43 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/fi/documents/product-information/cabazitaxel-accord-epar-product-information_fi.pdf)

svenska (SV) (864.72 KB - PDF)

**First published:**

17/12/2020

**Last updated:**

07/01/2026

[View](/sv/documents/product-information/cabazitaxel-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000320820 07/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cabazitaxel Accord : EPAR - All authorised presentations

English (EN) (11.39 KB - PDF)

**First published:** 28/10/2020

[View](/en/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-79)

български (BG) (50.48 KB - PDF)

**First published:**

28/10/2020

[View](/bg/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.18 KB - PDF)

**First published:**

28/10/2020

[View](/es/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49.18 KB - PDF)

**First published:**

28/10/2020

[View](/cs/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (11.23 KB - PDF)

**First published:**

28/10/2020

[View](/da/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (43.77 KB - PDF)

**First published:**

28/10/2020

[View](/de/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.37 KB - PDF)

**First published:**

28/10/2020

[View](/et/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (51.33 KB - PDF)

**First published:**

28/10/2020

[View](/el/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (11.51 KB - PDF)

**First published:**

28/10/2020

[View](/fr/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (47.9 KB - PDF)

**First published:**

28/10/2020

[View](/hr/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.32 KB - PDF)

**First published:**

28/10/2020

[View](/is/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.54 KB - PDF)

**First published:**

28/10/2020

[View](/it/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (49.38 KB - PDF)

**First published:**

28/10/2020

[View](/lv/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.67 KB - PDF)

**First published:**

28/10/2020

[View](/lt/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.23 KB - PDF)

**First published:**

28/10/2020

[View](/hu/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (49.74 KB - PDF)

**First published:**

28/10/2020

[View](/mt/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.49 KB - PDF)

**First published:**

28/10/2020

[View](/nl/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.43 KB - PDF)

**First published:**

28/10/2020

[View](/no/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.02 KB - PDF)

**First published:**

28/10/2020

[View](/pl/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (11.61 KB - PDF)

**First published:**

28/10/2020

[View](/pt/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (48 KB - PDF)

**First published:**

28/10/2020

[View](/ro/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.25 KB - PDF)

**First published:**

28/10/2020

[View](/sk/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (28.02 KB - PDF)

**First published:**

28/10/2020

[View](/sl/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.31 KB - PDF)

**First published:**

28/10/2020

[View](/fi/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (11.51 KB - PDF)

**First published:**

28/10/2020

[View](/sv/documents/all-authorised-presentations/cabazitaxel-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cabazitaxel Accord Active substance cabazitaxel International non-proprietary name (INN) or common name cabazitaxel Therapeutic area (MeSH) Prostatic Neoplasms, Castration-Resistant Anatomical therapeutic chemical (ATC) code L01CD04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

## Authorisation details

EMA product number EMEA/H/C/005178

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 30/04/2020 Marketing authorisation issued 28/08/2020 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cabazitaxel Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (350.86 KB - PDF)

**First published:** 07/05/2025

**Last updated:** 07/01/2026

[View](/en/documents/procedural-steps-after/cabazitaxel-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cabazitaxel Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (110.61 KB - PDF)

**First published:** 26/01/2022

**Last updated:** 07/05/2025

[View](/en/documents/procedural-steps-after/cabazitaxel-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Cabazitaxel Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/267872/2020

English (EN) (386.03 KB - PDF)

**First published:** 28/10/2020

[View](/en/documents/assessment-report/cabazitaxel-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cabazitaxel Accord

Adopted

Reference Number: EMA/CHMP/200669/2020

English (EN) (154.77 KB - PDF)

**First published:** 30/04/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cabazitaxel-accord_en.pdf)

#### News on Cabazitaxel Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020) 30/04/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Cabazitaxel Accord : EPAR - Product information - tracked changes

English (EN) (543.19 KB - DOCX)

**First published:** 07/05/2025

**Last updated:** 07/01/2026

[View](/en/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-1)

български (BG) (1.97 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/bg/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_bg.docx)

español (ES) (1.98 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/es/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_es.docx)

čeština (CS) (924.08 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/cs/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (1.98 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/da/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (1.6 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/de/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (716.95 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/et/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (623.84 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/el/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_el.docx)

français (FR) (1.88 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/fr/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (618.59 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/hr/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (431.31 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/is/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_is.docx)

italiano (IT) (2 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/it/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (1.93 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/lv/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (1.89 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/lt/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (1.93 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/hu/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (1.37 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/mt/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (668.85 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/nl/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (1.99 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/no/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_no.docx)

polski (PL) (758.19 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/pl/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_pl.docx)

português (PT) (905.78 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/pt/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_pt.docx)

română (RO) (1.97 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/ro/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (1.25 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/sk/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (678.99 KB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/sl/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (2.02 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/fi/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (1.94 MB - DOCX)

**First published:**

07/05/2025

**Last updated:**

07/01/2026

[View](/sv/documents/product-information-tracked-changes/cabazitaxel-accord-epar-product-information-tracked-changes_sv.docx)

#### More information on Cabazitaxel Accord

Cabazitaxel Accord : Letter to healthcare professionals about risk of mix-ups with Jevtana (cabazitaxel)

Reference Number: EMA/243153/2020

English (EN) (115.56 KB - PDF)

**First published:** 28/10/2020

[View](/en/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_en.pdf)

[Other languages (22)](#file-language-dropdown-27)

български (BG) (128.38 KB - PDF)

**First published:**

28/10/2020

[View](/bg/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_bg.pdf)

español (ES) (113.97 KB - PDF)

**First published:**

28/10/2020

[View](/es/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_es.pdf)

čeština (CS) (129.24 KB - PDF)

**First published:**

28/10/2020

[View](/cs/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_cs.pdf)

dansk (DA) (115.2 KB - PDF)

**First published:**

28/10/2020

[View](/da/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_da.pdf)

Deutsch (DE) (118.88 KB - PDF)

**First published:**

28/10/2020

[View](/de/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_de.pdf)

eesti keel (ET) (115.38 KB - PDF)

**First published:**

28/10/2020

[View](/et/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_et.pdf)

ελληνικά (EL) (128.77 KB - PDF)

**First published:**

28/10/2020

[View](/el/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_el.pdf)

français (FR) (117.92 KB - PDF)

**First published:**

28/10/2020

[View](/fr/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_fr.pdf)

hrvatski (HR) (116.49 KB - PDF)

**First published:**

28/10/2020

[View](/hr/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_hr.pdf)

italiano (IT) (123.84 KB - PDF)

**First published:**

28/10/2020

[View](/it/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_it.pdf)

latviešu valoda (LV) (138.32 KB - PDF)

**First published:**

28/10/2020

[View](/lv/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_lv.pdf)

lietuvių kalba (LT) (117.94 KB - PDF)

**First published:**

28/10/2020

[View](/lt/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_lt.pdf)

magyar (HU) (119.01 KB - PDF)

**First published:**

28/10/2020

[View](/hu/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_hu.pdf)

Malti (MT) (119.47 KB - PDF)

**First published:**

28/10/2020

[View](/mt/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_mt.pdf)

Nederlands (NL) (115.99 KB - PDF)

**First published:**

28/10/2020

[View](/nl/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_nl.pdf)

polski (PL) (119.77 KB - PDF)

**First published:**

28/10/2020

[View](/pl/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_pl.pdf)

português (PT) (115.26 KB - PDF)

**First published:**

28/10/2020

[View](/pt/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_pt.pdf)

română (RO) (117.39 KB - PDF)

**First published:**

28/10/2020

[View](/ro/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_ro.pdf)

slovenčina (SK) (119.97 KB - PDF)

**First published:**

28/10/2020

[View](/sk/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_sk.pdf)

slovenščina (SL) (115.18 KB - PDF)

**First published:**

28/10/2020

[View](/sl/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_sl.pdf)

Suomi (FI) (113.05 KB - PDF)

**First published:**

28/10/2020

[View](/fi/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_fi.pdf)

svenska (SV) (116.69 KB - PDF)

**First published:**

28/10/2020

[View](/sv/documents/medication-error/cabazitaxel-accord-letter-healthcare-professionals-about-risk-mix-ups-jevtana-cabazitaxel_sv.pdf)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Cabazitaxel Accord

- [Cabazitaxel Accord - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/cabazitaxel-accord)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/01/2026

## Share this page

[Back to top](#main-content)